+ Watch OPTR.DL
on My Watchlist
A biopharmaceutical company focused on discovering, developing and commercializing innovative anti-infective products.
Optimer stock is weathering yet another quarter of disappointing Dificid revenues by floating the old "strategic alternatives" flag. Sometimes the sale happens, more often that not it doesn't. I remember that tactic didn't work out very well for Savient. Dificid has been a confusing underperformer, given that clostridium difficile infection continues to be a crisis in the US health care system and the available therapeutics are clearly insufficient. Perhaps a larger pharma feels like they have the skills to make Dificid more profitable, but I suspect antibiotics are a relatively low priority for most of those companies. Even if a buyout does occur, I think it will take long enough that most of the short-term momo traders will get bored and exit.
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions